Stay updated on Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page.

Latest updates to the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page
- Check6 days agoChange DetectedVersion 34 updates the record by renaming the study to include Placebo With ADT and adding the Contacts/Locations, Study Design, Study Status, and Study Identification sections. These changes align the study's identification with the protocol and provide essential administrative details for tracking.SummaryDifference0.5%

- Check13 days agoChange DetectedAdded Revision: v3.4.2 to the history. Removed the government funding lapse notice and operating-status guidance that previously appeared on the page.SummaryDifference0.5%

- Check20 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and the NIH Clinical Center's status. Updated the page revision to v3.4.1, with the previous revision v3.4.0 removed.SummaryDifference0.5%

- Check28 days agoChange DetectedThe page now shows a Show glossary option and a legend for color-coded changes (green for additions, red for deletions). It also introduces the latest revision label (Revision: v3.4.0) and a minor capitalization change in 'No FEAR Act Data'.SummaryDifference0.7%

- Check42 days agoChange DetectedThe history now shows Revision: v3.3.4 and omits Revision: v3.3.3, which affects only revision history metadata and does not alter the study's core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedNew history entries were added for Contacts/Locations, Study Design, and Study Status, along with a new version (32) and Revision: v3.3.3; the entry for HHS Vulnerability Disclosure was removed.SummaryDifference0.6%

Stay in the know with updates to Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Darolutamide in Hormone Sensitive Prostate Cancer Clinical Trial page.